TB-500 vs Thymosin Alpha-1
Both TB-500 and Thymosin Alpha-1 are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
TB-500
Evidence BThymosin Beta-4 Fragment
A synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'
View full TB-500 profile →Thymosin Alpha-1
Evidence AThymosin Alpha-1 (Tα1)
A 28-amino-acid thymic peptide that matures and modulates T-cells. Used internationally as an adjunct in hepatitis, sepsis, and immune-compromised cancer care.
View full Thymosin Alpha-1 profile →Side-by-Side
| Attribute | TB-500 | Thymosin Alpha-1 |
|---|---|---|
| Evidence Grade | B | A |
| FDA Status | Not FDA-approved — Category 2 (reclassification to Cat 1 expected 2026) | Approved in 35+ countries for hepatitis B/C, immune support; not FDA-approved in US (orphan-drug designations) |
| Typical Dose | 2 mg twice weekly (subcutaneous) | 1.6 mg twice weekly (subcutaneous) |
| Clinics Indexed | 183 | 192 |
| Categories | recovery, anti-inflammatory | immune, anti-inflammatory |
Key reported benefits — TB-500
- ✓Wound healing
- ✓Anti-inflammation
- ✓Tissue regeneration
- ✓Flexibility
Key reported benefits — Thymosin Alpha-1
- ✓T-cell maturation
- ✓Antiviral immunity
- ✓Tumor immune support
- ✓Sepsis adjunct
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.